Literature DB >> 15686632

Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between.

Natalia Jura1, Herbert Archer, Dafna Bar-Sagi.   

Abstract

Pancreatic cancer is a challenging disease for patients, doctors and researchers who for decades have searched for a cure for this deadly malignancy. Although existing mouse models of pancreatic cancer have shed light on the mechanistic basis of the neoplastic conversion of the pancreas, their impact in terms of offering new diagnostics and therapeutic modalities remains limited. Chronic pancreatitis is an inflammatory disease of the pancreas that is associated with a gradual damage of the organ and an increased risk of developing neoplastic lesions. In this review, we propose that detailed studies of chronic inflammatory processes in the pancreas will provide insights into the evolution of pancreatic cancer. This information may prove useful in the design of effective therapeutic strategies to battle the disease.

Entities:  

Mesh:

Year:  2005        PMID: 15686632     DOI: 10.1038/sj.cr.7290269

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  28 in total

Review 1.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Lei Zheng; Jing Xue; Elizabeth M Jaffee; Aida Habtezion
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 2.  Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer.

Authors:  Hideya Onishi; Mitsuo Katano
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Pancreatic Inflammation Redirects Acinar to β Cell Reprogramming.

Authors:  Hannah W Clayton; Anna B Osipovich; Jennifer S Stancill; Judsen D Schneider; Pedro G Vianna; Carolyn M Shanks; Weiping Yuan; Guoqiang Gu; Elisabetta Manduchi; Christian J Stoeckert; Mark A Magnuson
Journal:  Cell Rep       Date:  2016-11-15       Impact factor: 9.423

4.  Risk factors for pancreatic cancer: case-control study.

Authors:  Manal M Hassan; Melissa L Bondy; Robert A Wolff; James L Abbruzzese; Jean-Nicolas Vauthey; Peter W Pisters; Douglas B Evans; Rabia Khan; Ta-Hsu Chou; Renato Lenzi; Li Jiao; Donghui Li
Journal:  Am J Gastroenterol       Date:  2007-08-31       Impact factor: 10.864

5.  Orthotopic inflammation-related pancreatic carcinogenesis in a wild-type mouse induced by combined application of caerulein and dimethylbenzanthracene.

Authors:  Chen Liang; Zhen Wang; Li Wu; Chen Wang; Bao-Hua Yu; Xiu-Zhong Yao; Xiao-Lin Wang; Ying-Yi Li
Journal:  Tumour Biol       Date:  2015-04-29

6.  Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.

Authors:  Jennifer Kl Colby; Russell D Klein; Mark J McArthur; Claudio J Conti; Kaoru Kiguchi; Toru Kawamoto; Penny K Riggs; Amy I Pavone; Janet Sawicki; Susan M Fischer
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  Polymorphisms in tumour necrosis factor alpha (TNFalpha) gene in patients with acute pancreatitis.

Authors:  Gül Ozhan; Hakan T Yanar; Cemalettin Ertekin; Buket Alpertunga
Journal:  Mediators Inflamm       Date:  2010-04-14       Impact factor: 4.711

Review 8.  Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.

Authors:  Kristina Blaslov; Tomislav Bulum; Karin Zibar; Lea Duvnjak
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Authors:  P C Butler; A V Matveyenko; S Dry; A Bhushan; R Elashoff
Journal:  Diabetologia       Date:  2009-11-06       Impact factor: 10.122

10.  GLP-1-based therapy for diabetes: what you do not know can hurt you.

Authors:  Peter C Butler; Sarah Dry; Robert Elashoff
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.